UK Markets closed

Vifor Pharma AG (GNHAY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
37.700.00 (0.00%)
At close: 10:54AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close37.70
Open37.70
BidN/A x N/A
AskN/A x N/A
Day's range37.70 - 37.70
52-week range25.50 - 37.70
Volume25
Avg. volume27
Market cap12.225B
Beta (5Y monthly)1.37
PE ratio (TTM)26.85
EPS (TTM)1.40
Earnings dateN/A
Forward dividend & yield0.41 (1.15%)
Ex-dividend date12 May 2022
1y target estN/A
  • Business Wire

    Finalization of Vifor Pharma acquisition

    MELBOURNE, Australia & ST. GALLEN, Switzerland, August 02, 2022--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005796/en/

  • Business Wire

    Extension of the postponement of the settlement of Vifor Pharma tender offer

    MELBOURNE, Australia & ST. GALLEN, Switzerland, July 13, 2022--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006199/en/

  • Reuters

    EU regulators investigate Vifor Pharma over anti-competitive behaviour

    EU antitrust regulators are investigating whether Vifor Pharma, which is being acquired by CSL Ltd, disparaged its rival Pharmacosmos in order to hinder competition with its blockbuster iron deficiency medicine Ferinject. The European Commission, which opened the probe on Monday, said it was concerned that Swiss drugmaker Vifor Pharma pursued a misleading marketing campaign, primarily targeting healthcare professionals.